FDA Approves Replimune’s Melanoma Drug on Third Attempt

FDA Approves Replimune’s Melanoma Drug on Third Attempt



FDA Approves Replimune’s Melanoma Drug on Third Attempt
The agency had turned down two earlier applications over clinical data-quality concerns.